Biogen launches Phase 3 BRAVE study to assess omaveloxolone's effects in children with Friedreich ataxia. Quiver AI Summary Biogen Inc. has launched the BRAVE study, a global Phase 3 clinical ...

Michael Gehr, of Edmond, and his family are on a mission to help find a cure for a rare genetic disease that he was diagnosed ...